...
首页> 外文期刊>Vascular pharmacology >Multiple paracrine factors secreted by mesenchymal stem cells contribute to angiogenesis
【24h】

Multiple paracrine factors secreted by mesenchymal stem cells contribute to angiogenesis

机译:间充质干细胞分泌的多种旁分泌因子促进血管生成

获取原文
获取原文并翻译 | 示例

摘要

The therapeutic effects of stem cell transplantation in ischemic disease are mediated by the production of paracrine bioactive factors. However, the bioactive factors secreted by human mesenchymal stem cells (hMSCs) and their angiogenic activity are not clearly identified or determined. We here found that hMSC-derived conditioned media (hMSC-CdM) stimulated in vitro angiogenic activity of endothelial cells and contained significant levels of various growth factors and cytokines, such as vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), and transforming growth factor-beta1 (TGF-beta 1). The angiogenic activity of hMSC-CdM was significantly inhibited by pretreatment with neutralizing antibodies against VEGF, MCP-1, and IL-6, but not against TGF-beta 1 and HGF. A mixture of those inhibitory antibodies blocked CdM-mediated activation of angiogenic signals, as well as inhibited CdM-mediated in vivo angiogenesis. Moreover, local injection of CdM increased angiogenesis and promoted blood flow in mice with hindlimb ischemia, and these effects were inhibited by co-treatment with these inhibitory antibodies. These results indicate that hMSC-CdM represents a promising cell-free therapeutic strategy for neovascularization in ischemic diseases. These results suggest the combination of VEGF, MCP-1, and IL-6 as a commercial application for therapeutic angiogenesis. (C) 2014 Elsevier Inc. All rights reserved.
机译:干细胞移植在缺血性疾病中的治疗作用是由旁分泌生物活性因子的产生介导的。但是,人类间充质干细胞(hMSCs)分泌的生物活性因子及其血管生成活性尚不清楚。我们在这里发现,hMSC衍生的条件培养基(hMSC-CdM)刺激了内皮细胞的体外血管生成活性,并包含大量的各种生长因子和细胞因子,例如血管内皮生长因子(VEGF),肝细胞生长因子(HGF),单核细胞趋化蛋白1(MCP-1),白介素6(IL-6)和转化生长因子β1(TGF-β1)。用抗VEGF,MCP-1和IL-6的中和抗体预处理可显着抑制hMSC-CdM的血管生成活性,但不抗TGF-beta 1和HGF。这些抑制性抗体的混合物阻断了CdM介导的血管生成信号的激活,以及抑制了CdM介导的体内血管生成。此外,局部注射CdM可以增加后肢缺血小鼠的血管生成并促进血流量,并且通过与这些抑制性抗体共同治疗可抑制这些作用。这些结果表明,hMSC-CdM代表了一种有希望的缺血性疾病新血管形成的无细胞治疗策略。这些结果表明,VEGF,MCP-1和IL-6的组合作为治疗性血管生成的商业应用。 (C)2014 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号